Cargando…
Will availability of inhaled human insulin (Exubera(®)) improve management of type 2 diabetes? The design of the Real World trial
BACKGROUND: Common deterrents to insulin therapy for both physicians and patients are the complexity and burden of daily injections. In January 2006, the first inhaled human insulin (INH, Exubera(® )(insulinhuman [rDNA origin])InhalationPowder) was approved for use in adult patients with type 1 diab...
Autores principales: | Freemantle, Nick, Strack, Thomas R |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2006
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1564148/ https://www.ncbi.nlm.nih.gov/pubmed/16901335 http://dx.doi.org/10.1186/1745-6215-7-25 |
Ejemplares similares
-
Exubera(®) (inhaled insulin): an evidence-based review of its effectiveness in the management of diabetes
por: Profit, Louise
Publicado: (2005) -
Inhaled human insulin (Exubera®): clinical profile and patient considerations
por: Barnett, Anthony H, et al.
Publicado: (2007) -
Two-Year Pulmonary Safety and Efficacy of Inhaled Human Insulin (Exubera) in Adult Patients With Type 2 Diabetes
por: Rosenstock, Julio, et al.
Publicado: (2008) -
Pulmonary and cardiovascular safety of inhaled insulin in routine practice: The Exubera Large Simple Trial (VOLUME)
por: Gatto, Nicolle M., et al.
Publicado: (2019) -
Design of the BiRmingham Early Detection In untREated psyChosis Trial (REDIRECT): cluster randomised controlled trial of general practitioner education in detection of first episode psychosis [ISRCTN87898421]
por: Tait, Lynda, et al.
Publicado: (2005)